icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
 Back grey_arrow_rt.gif
 
 
 
Resistance Analysis of Treatment-Experienced Genotype 1 and 3 HCV-Infected Patients Treated With Sofosbuvir in Combination With GS-5816 ± Ribavirin for 12 Weeks
 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Brian P. Doehle,1 Evguenia S. Svarovskaia,1 Krishna Chodavarapu,1 John McNally,1 Stephen Pianko,2 Stuart K. Roberts,3 Diana M. Brainard,1 Michael D. Miller,1 Hongmei Mo1
1Gilead Sciences, Inc., Foster City, California, USA; 2Monash Health and Monash University, Clayton, Victoria, Australia; 3Alfred Health and Monash University, Melbourne, Victoria, Australia

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

References
1. Jacobson IM, et al. N Engl J Med 2013;368:1867-77;
2. Lawitz E, et al. N Engl J Med 2013;368:1878-87;
3. Cheng G, et al. EASL 2013, poster 1191;
4. German P, et al. EASL 2013, poster 1195;
5. Lawitz E, et al. EASL 2013, poster 1082;
6. Pianko S, et al. AASLD 2014, oral 197.